Concerto HealthAI Appoints Warren A. Whyte, PhD, Vice President of Strategic Partnerships & Customer Success, and Paul Park, SVP, Corporate Development

Two RWE innovators position company for pharma- and patient-centered partnerships with its leading oncology Real-World Data and eurekaHealth family of AI-enabled technologies

Boston, MA – May 6, 2020 – Concerto HealthAI, the leader in Real-World Evidence (RWE) and AI solutions for the life sciences and healthcare industries, is pleased to welcome Warren A. Whyte, PhD, as Vice President of Strategic Partnerships and Customer Success, and Paul Park as Senior Vice President of Corporate Development.

Dr. Whyte joins Concerto HealthAI after spending the last several years at Accenture, where he led the strategic delivery of RWE offerings for leading drug and medical device companies across medical affairs, R&D and commercial functions. Prior to Accenture, Dr. Whyte consulted for several biopharmaceutical companies, and led research in genomics and molecular biology that preceded the creation of Syros Pharmaceuticals, a venture-backed gene therapy company. Dr. Whyte has published in several peer-reviewed scientific journals. He has a BS in molecular and cell biology from Cornell University and a PhD in genomics from MIT.

Mr. Park previously served as Head of Strategic Partnerships at Aetion. Mr. Park also held strategic leadership roles at Amgen that included the acquisition of Enbrel (third highest-selling drug globally at its peak) and Tularik (which became Amgen’s research center in South San Francisco). Mr. Park has served as the Executive Director of First Fruit, Inc., deploying grants and impact investments to more than 1,000 organizations working in 100 of the poorest and least-free nations in the world. Mr. Park has a BA from Brown University and an MBA from the Wharton School of Business.

“I am thrilled to welcome Warren and Paul in the midst of the most profound changes in the healthcare system of our lifetime,” said Jeff Elton, PhD and CEO of Concerto HealthAI. “Their respective experience advancing novel RWE solutions, founded on both data and RWE technologies, will accelerate our mission to bring the most precise and innovative therapeutics to patients faster and more confidently.”

“I’m excited to join the Concerto HealthAI team during this unprecedented time,” said Dr. Whyte, who will oversee customer delivery of Concerto HealthAI’s data and technology products. “I’m looking forward to advancing our partnerships with life sciences and healthcare customers in delivering truly innovative data and AI-powered medicines to patients.”

“At a time when clinical trial activity has been dramatically impeded by the global pandemic, I am invigorated by being able to join an organization so well-positioned to ensure that vital cancer therapies can continue to be investigated for maximum patient benefit,” said Mr. Park.